M1 KLINIKEN AG (M12.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:M12 - DE000A0STSQ8 - Common Stock
18.16 EUR
-0.84 (-4.42%)
M12 gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 28 industry peers in the Health Care Providers & Services industry. M12 has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. M12 has a decent growth rate and is not valued too expensively. This makes M12 very considerable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year M12 was profitable.
In the past year M12 had a positive cash flow from operations.
M12 had positive earnings in each of the past 5 years.
Each year in the past 5 years M12 had a positive operating cash flow.
1.2 Ratios
The Return On Assets of M12 (8.73%) is better than 96.43% of its industry peers.
With a decent Return On Equity value of 15.03%, M12 is doing good in the industry, outperforming 78.57% of the companies in the same industry.
M12's Return On Invested Capital of 13.44% is amongst the best of the industry. M12 outperforms 89.29% of its industry peers.
The Average Return On Invested Capital over the past 3 years for M12 is in line with the industry average of 6.91%.
The last Return On Invested Capital (13.44%) for M12 is above the 3 year average (7.72%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROIC | 13.44% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
1.3 Margins
The Profit Margin of M12 (5.00%) is better than 82.14% of its industry peers.
M12's Profit Margin has declined in the last couple of years.
M12 has a better Operating Margin (8.52%) than 71.43% of its industry peers.
M12's Operating Margin has declined in the last couple of years.
M12's Gross Margin of 19.29% is in line compared to the rest of the industry. M12 outperforms 42.86% of its industry peers.
In the last couple of years the Gross Margin of M12 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% |
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
2. Health
2.1 Basic Checks
M12 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, M12 has less shares outstanding
Compared to 5 years ago, M12 has more shares outstanding
Compared to 1 year ago, M12 has a worse debt to assets ratio.
2.2 Solvency
M12 has an Altman-Z score of 5.84. This indicates that M12 is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of M12 (5.84) is better than 100.00% of its industry peers.
M12 has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
M12's Debt to FCF ratio of 0.70 is amongst the best of the industry. M12 outperforms 100.00% of its industry peers.
M12 has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.05, M12 belongs to the top of the industry, outperforming 96.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 5.84 |
ROIC/WACC1.86
WACC7.21%
2.3 Liquidity
M12 has a Current Ratio of 2.06. This indicates that M12 is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of M12 (2.06) is better than 89.29% of its industry peers.
M12 has a Quick Ratio of 1.35. This is a normal value and indicates that M12 is financially healthy and should not expect problems in meeting its short term obligations.
With an excellent Quick ratio value of 1.35, M12 belongs to the best of the industry, outperforming 82.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 10.36% over the past year.
M12 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.97% yearly.
Looking at the last year, M12 shows a small growth in Revenue. The Revenue has grown by 6.52% in the last year.
M12 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 34.44% yearly.
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
3.2 Future
M12 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.18% yearly.
M12 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.24% yearly.
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 19.32, which indicates a rather expensive current valuation of M12.
Compared to the rest of the industry, the Price/Earnings ratio of M12 is on the same level as its industry peers.
The average S&P500 Price/Earnings ratio is at 26.60. M12 is valued slightly cheaper when compared to this.
With a Price/Forward Earnings ratio of 15.65, M12 is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of M12 is on the same level as its industry peers.
When comparing the Price/Forward Earnings ratio of M12 to the average of the S&P500 Index (23.23), we can say M12 is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.32 | ||
| Fwd PE | 15.65 |
4.2 Price Multiples
M12's Enterprise Value to EBITDA ratio is in line with the industry average.
The rest of the industry has a similar Price/Free Cash Flow ratio as M12.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.36 | ||
| EV/EBITDA | 9.41 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
M12 has a very decent profitability rating, which may justify a higher PE ratio.
M12's earnings are expected to grow with 19.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.72
PEG (5Y)2.43
EPS Next 2Y14.78%
EPS Next 3Y19.18%
5. Dividend
5.1 Amount
M12 has a Yearly Dividend Yield of 2.80%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 1.47, M12 pays a better dividend. On top of this M12 pays more dividend than 89.29% of the companies listed in the same industry.
M12's Dividend Yield is a higher than the S&P500 average which is at 2.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.8% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
DPN/A
EPS Next 2Y14.78%
EPS Next 3Y19.18%
FRA:M12 (1/2/2026, 7:00:00 PM)
18.16
-0.84 (-4.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.52%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap356.66M
Revenue(TTM)354.98M
Net Income(TTM)17.74M
Analysts85
Price Target27.03 (48.84%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.8% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.32 | ||
| Fwd PE | 15.65 | ||
| P/S | 1 | ||
| P/FCF | 13.36 | ||
| P/OCF | 13.19 | ||
| P/B | 3.02 | ||
| P/tB | 12.99 | ||
| EV/EBITDA | 9.41 |
EPS(TTM)0.94
EY5.18%
EPS(NY)1.16
Fwd EY6.39%
FCF(TTM)1.36
FCFY7.49%
OCF(TTM)1.38
OCFY7.58%
SpS18.07
BVpS6.01
TBVpS1.4
PEG (NY)3.72
PEG (5Y)2.43
Graham Number11.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROCE | 19.39% | ||
| ROIC | 13.44% | ||
| ROICexc | 18.99% | ||
| ROICexgc | 105.66% | ||
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% | ||
| FCFM | 7.52% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
ROICexc(3y)9.69%
ROICexc(5y)8.26%
ROICexgc(3y)31.7%
ROICexgc(5y)24.88%
ROCE(3y)11.15%
ROCE(5y)8.88%
ROICexgc growth 3Y38.16%
ROICexgc growth 5Y31.27%
ROICexc growth 3Y22.22%
ROICexc growth 5Y5.12%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
F-Score9
Asset Turnover1.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.17 | ||
| Cap/Depr | 6.62% | ||
| Cap/Sales | 0.1% | ||
| Interest Coverage | 21.13 | ||
| Cash Conversion | 76.34% | ||
| Profit Quality | 150.51% | ||
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 5.84 |
F-Score9
WACC7.21%
ROIC/WACC1.86
Cap/Depr(3y)22.84%
Cap/Depr(5y)24.89%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.51%
Profit Quality(3y)272.44%
Profit Quality(5y)207.18%
High Growth Momentum
Growth
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
EBIT growth 1Y32.15%
EBIT growth 3Y30.31%
EBIT growth 5Y27.31%
EBIT Next Year30.73%
EBIT Next 3Y27.49%
EBIT Next 5YN/A
FCF growth 1Y132.58%
FCF growth 3Y27.23%
FCF growth 5YN/A
OCF growth 1Y108.94%
OCF growth 3Y24.88%
OCF growth 5YN/A
M1 KLINIKEN AG / M12.DE FAQ
Can you provide the ChartMill fundamental rating for M1 KLINIKEN AG?
ChartMill assigns a fundamental rating of 6 / 10 to M12.DE.
What is the valuation status for M12 stock?
ChartMill assigns a valuation rating of 4 / 10 to M1 KLINIKEN AG (M12.DE). This can be considered as Fairly Valued.
How profitable is M1 KLINIKEN AG (M12.DE) stock?
M1 KLINIKEN AG (M12.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for M12 stock?
The Price/Earnings (PE) ratio for M1 KLINIKEN AG (M12.DE) is 19.32 and the Price/Book (PB) ratio is 3.02.
What is the financial health of M1 KLINIKEN AG (M12.DE) stock?
The financial health rating of M1 KLINIKEN AG (M12.DE) is 8 / 10.